230 related articles for article (PubMed ID: 7554037)
1. Limited sampling models for simultaneous estimation of the pharmacokinetics of irinotecan and its active metabolite SN-38.
Chabot GG
Cancer Chemother Pharmacol; 1995; 36(6):463-72. PubMed ID: 7554037
[TBL] [Abstract][Full Text] [Related]
2. Population pharmacokinetics and pharmacodynamics of irinotecan (CPT-11) and active metabolite SN-38 during phase I trials.
Chabot GG; Abigerges D; Catimel G; Culine S; de Forni M; Extra JM; Mahjoubi M; Hérait P; Armand JP; Bugat R
Ann Oncol; 1995 Feb; 6(2):141-51. PubMed ID: 7786822
[TBL] [Abstract][Full Text] [Related]
3. A limited sampling model for estimating pharmacokinetics of CPT-11 and its metabolite SN-38.
Sasaki Y; Mizuno S; Fujii H; Ohtsu T; Wakita H; Igarashi T; Itoh K; Sekine I; Miyata Y; Saijo N
Jpn J Cancer Res; 1995 Jan; 86(1):117-23. PubMed ID: 7737903
[TBL] [Abstract][Full Text] [Related]
4. Limited-sampling models for irinotecan pharmacokinetics-pharmacodynamics: prediction of biliary index and intestinal toxicity.
Mick R; Gupta E; Vokes EE; Ratain MJ
J Clin Oncol; 1996 Jul; 14(7):2012-9. PubMed ID: 8683231
[TBL] [Abstract][Full Text] [Related]
5. Limited sampling models for CPT-11, SN-38, and SN-38 glucuronide.
Sloan JA; Atherton P; Reid J; Pitot HC; Erlichman C; Schaaf L
Cancer Chemother Pharmacol; 2001 Sep; 48(3):241-9. PubMed ID: 11592347
[TBL] [Abstract][Full Text] [Related]
6. Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients.
Abigerges D; Chabot GG; Armand JP; Hérait P; Gouyette A; Gandia D
J Clin Oncol; 1995 Jan; 13(1):210-21. PubMed ID: 7799022
[TBL] [Abstract][Full Text] [Related]
7. Phase I and pharmacokinetic study of irinotecan (CPT-11) administered daily for three consecutive days every three weeks in patients with advanced solid tumors.
Catimel G; Chabot GG; Guastalla JP; Dumortier A; Cote C; Engel C; Gouyette A; Mathieu-Boué A; Mahjoubi M; Clavel M
Ann Oncol; 1995 Feb; 6(2):133-40. PubMed ID: 7786821
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological correlation between total drug concentration and lactones of CPT-11 and SN-38 in patients treated with CPT-11.
Sasaki Y; Yoshida Y; Sudoh K; Hakusui H; Fujii H; Ohtsu T; Wakita H; Igarashi T; Itoh K
Jpn J Cancer Res; 1995 Jan; 86(1):111-6. PubMed ID: 7737902
[TBL] [Abstract][Full Text] [Related]
9. Clinical pharmacokinetics of irinotecan.
Chabot GG
Clin Pharmacokinet; 1997 Oct; 33(4):245-59. PubMed ID: 9342501
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics and pharmacodynamics of irinotecan during a phase II clinical trial in colorectal cancer. Pharmacology and Molecular Mechanisms Group of the European Organization for Research and Treatment of Cancer.
Canal P; Gay C; Dezeuze A; Douillard JY; Bugat R; Brunet R; Adenis A; Herait P; Lokiec F; Mathieu-Boue A
J Clin Oncol; 1996 Oct; 14(10):2688-95. PubMed ID: 8874328
[TBL] [Abstract][Full Text] [Related]
11. Estimation of the area under the concentration-versus-time curve of carboplatin following irinotecan using a limited sampling model.
Asai G; Ando Y; Saka H; Ando M; Sugiura S; Sakai S; Hasegawa Y; Shimokata K
Eur J Clin Pharmacol; 1998; 54(9-10):725-7. PubMed ID: 9923575
[TBL] [Abstract][Full Text] [Related]
12. Simultaneous determination of the camptothecin analogue CPT-11 and its active metabolite SN-38 by high-performance liquid chromatography: application to plasma pharmacokinetic studies in cancer patients.
Barilero I; Gandia D; Armand JP; Mathieu-Boué A; Ré M; Gouyette A; Chabot GG
J Chromatogr; 1992 Mar; 575(2):275-80. PubMed ID: 1629304
[TBL] [Abstract][Full Text] [Related]
13. Sparse-data set analysis for irinotecan and SN-38 pharmacokinetics in cancer patients co-treated with cisplatin.
Mathijssen RH; van Alphen RJ; de Jonge MJ; Verweij J; de Bruijn P; Loos WJ; Nooter K; Vernillet L; Stoter G; Sparreboom A
Anticancer Drugs; 1999 Jan; 10(1):9-16. PubMed ID: 10194542
[TBL] [Abstract][Full Text] [Related]
14. Simple and rapid determination of irinotecan and its metabolite SN-38 in plasma by high-performance liquid-chromatography: application to clinical pharmacokinetic studies.
Escoriaza J; Aldaz A; Castellanos C; Calvo E; Giráldez J
J Chromatogr B Biomed Sci Appl; 2000 Apr; 740(2):159-68. PubMed ID: 10821401
[TBL] [Abstract][Full Text] [Related]
15. Salivary drug monitoring of irinotecan and its active metabolite in cancer patients.
Takahashi T; Fujiwara Y; Sumiyoshi H; Isobe T; Yamaoka N; Yamakido M
Cancer Chemother Pharmacol; 1997; 40(5):449-52. PubMed ID: 9272124
[TBL] [Abstract][Full Text] [Related]
16. Plasma and cerebrospinal fluid pharmacokinetics of 9-aminocamptothecin (9-AC), irinotecan (CPT-11), and SN-38 in nonhuman primates.
Blaney SM; Takimoto C; Murry DJ; Kuttesch N; McCully C; Cole DE; Godwin K; Balis FM
Cancer Chemother Pharmacol; 1998; 41(6):464-8. PubMed ID: 9554590
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of CPT-11 in rhesus monkeys.
Inaba M; Ohnishi Y; Ishii H; Tanioka Y; Yoshida Y; Sudoh K; Hakusui H; Mizuno N; Ito K; Sugiyama Y
Cancer Chemother Pharmacol; 1998; 41(2):103-8. PubMed ID: 9443622
[TBL] [Abstract][Full Text] [Related]
18. Experimental antitumor activity and pharmacokinetics of the camptothecin analog irinotecan (CPT-11) in mice.
Bissery MC; Vrignaud P; Lavelle F; Chabot GG
Anticancer Drugs; 1996 Jun; 7(4):437-60. PubMed ID: 8826613
[TBL] [Abstract][Full Text] [Related]
19. Irinotecan in combination with thalidomide in patients with advanced solid tumors: a clinical study with pharmacodynamic and pharmacokinetic evaluation.
Allegrini G; Di Paolo A; Cerri E; Cupini S; Amatori F; Masi G; Danesi R; Marcucci L; Bocci G; Del Tacca M; Falcone A
Cancer Chemother Pharmacol; 2006 Nov; 58(5):585-93. PubMed ID: 16680463
[TBL] [Abstract][Full Text] [Related]
20. Phase I dose-finding and pharmacokinetic trial of irinotecan (CPT-11) administered every two weeks.
Rothenberg ML; Kuhn JG; Schaaf LJ; Rodriguez GI; Eckhardt SG; Villalona-Calero MA; Rinaldi DA; Hammond LA; Hodges S; Sharma A; Elfring GL; Petit RG; Locker PK; Miller LL; von Hoff DD
Ann Oncol; 2001 Nov; 12(11):1631-41. PubMed ID: 11822765
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]